our story

What if it’s not just you?

For millions of people around the world, lifestyle disorders are a fact of life.

learn more


Most of us share a common misconception that our metabolic disorder is a result of some kind of character failing.

But what if it wasn’t your lack of willpower or supposed bad choices holding you back? What if the missing link was the low levels of Akkermansia in your gut?

We can help you increase those levels.

What if it’s your level of Akkermansia?

Prof. Willem M. de Vos and Prof. Patrice D. Cani discovered that Akkermansia muciniphila helps maintain a healthy gut microbiome.

Too little of this bacterium and the gut barrier begins to leak, allowing harmful toxins and fat to enter the body. But we can undo the damage by restoring the natural level of the bacterium.


Enter The
Akkermansia CompanyTM

After Professors de Vos and Cani decoded and patented the Akkermansia bacterium, they founded The Akkermansia CompanyTM (previously known as A-mansia Biotech) so that they could share their breakthrough.

The missing link to overcoming lifestyle disorders?

Today, The Akkermansia CompanyTM aims to

Produce a range of pioneering solutions that help people live healthier, happier lives


Accelerate scientific research and understanding of the medical application


Start a global movement that helps liberate people from discomforting thoughts and help them to improve their health

We’re taking our message to all corners of the globe:

And what if it wasn’t you?
It’s time to discover the answer you’ve been looking for.

Our History


Akkermansia muciniphila isolation, identification and characterisation by Prof. Willem M. de Vos (Wageningen University – The Netherlands) and his team.

Prof. Willem M. de Vos


Collaboration between the teams of Prof. Willem M. de Vos (Wageningen University – The Netherlands) and Prof. Patrice D. Cani (UCLouvain – Belgium).


Demonstration of higher efficiency of the pasteurised Akkermansia muciniphila compared to the live bacterium in the prevention of gut barrier dysfunction, obesity, diabetes and related metabolic disorders in preclinical models of obesity.



First high-scale production of Akkermansia muciniphila at a quality level suitable to begin clinical studies. The ethical committee gives its approval for the Microbes4U study.


Publication of the Microbes4U© study results in Nature Medicine : the first randomised double-blind placebo-controlled pilot study in human volunteers demonstrates that daily administration of pasteurised Akkermansia muciniphila for 3 months is safe and well tolerated.

nature medicine


Application for the approval of pasteurised Akkermansia muciniphila as a novel food ingredient in the European Union.


Publication of the toxicological safety evaluation of pasteurised Akkermansia muciniphila.



First next generation bacterium to get EFSA approval.